Timothy Eugene Sullivan, Chief Financial Officer at Apellis Pharmaceuticals, Inc. (APLS), sold 75,458 shares at $27.86 ($2.1M) on 2025-09-08, disclosed to the SEC on 2025-09-10.
Scheduled sale ($2.1M) by Chief Financial Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $27.83 | 10,000 | $278K | 13.2% |
| 2 | $27.86 | 32,729 | $912K | 43.4% |
| 3 | $27.86 | 32,729 | $912K | 43.4% |
| Total | $27.86 avg | 75,458 | $2.1M | 100% |
| Filing → |
| APLS | SELL | 2026-01-15 | $86K | — | Filing → |
| APLS | SELL | 2025-10-23 | $280K | — | Filing → |
| APLS | SELL | 2025-01-30 | $16K | — | Filing → |